YHLO

Focus on healthcare, better life with technology In May of 2021, YHLO has successfully launched IPO and listed on Shanghai Stock Exchange (Stock code: 688575).

YHLO (EST. 2008) is an innovative and steadfastly growing company of immunoassay solutions headquartered in Shenzhen, China, specialized in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents by a team of experienced scientists and engineers.

04/09/2025

🔍 IL-6: Precision Marker for Inflammatory Storms

Interleukin-6 (IL-6) provides an early warning of infections and sepsis, helping clinicians to act quickly. Powered by YHLO’s high-precision CLIA platform, IL-6 testing enables accurate and dynamic tracking of inflammation levels for better clinical decisions.

For more information, please visit: https://en.szyhlo.com/

03/09/2025

🌡️ CRP – Classic Inflammation Biomarker

C-reactive protein (CRP) helps differentiate bacterial from viral infections and supports risk assessment for severe disease. YHLO’s high-sensitivity platform ensures accurate results to guide treatment adjustments.

For more information, please visit: https://en.szyhlo.com/

#

28/08/2025

🔬 Adiponectin: Your Early Warning Signal for Fatty Liver

Low adiponectin levels are linked to a 3–5× higher risk of developing fatty liver — and can predict disease onset 2–4 years in advance.

With its anti-inflammatory benefits and IVDR-certified accuracy, YHLO iFlash-Adiponectin helps you stay ahead of risk and guide early intervention with confidence.

26/08/2025

🔍 Fatty liver affects over 1 billion people globally — and should not be underestimated.

It can silently progress to fibrosis, cirrhosis, or even liver cancer, and increase the risk of type 2 diabetes and cardiovascular disease.

With IVDR-certified performance, YHLO iFlash-Adiponectin is your reliable solution for early assessment and risk prediction.

20/08/2025

🔬 Detect liver fibrosis early with YHLO’s comprehensive biomarker panel: HA, PIIINP, Col IV, and Laminin.

Our solution covers all stages (S0–S4), enhancing diagnostic accuracy and supporting treatment decisions.

18/08/2025

🧠 Diagnose autoimmune liver diseases with confidence.

YHLO’s SMA IgG and AMA-M2 tests offer high specificity for AIH and PBC, helping prevent misdiagnosis and overtreatment.

13/08/2025

🧫 Autoimmune liver diseases are complex—YHLO’s iFlash SMA IgG and AMA-M2 tests offer valuable tools to distinguish between AIH, PBC, PSC, and overlap syndromes.

Our accurate and automated CLIA solution helps clinicians classify liver conditions more precisely and guide better treatment planning.

11/08/2025

📢 We’re proud to announce that YHLO’s iFlash HBeAg, Anti-HBe, Anti-HBc, and Anti-HCV reagents have officially received IVDR certific

These hepatitis B and C markers deliver 100% sensitivity and specificity (or near-perfect) to support confident clinical decisions across labs. More IVDR updates coming soon!

06/08/2025

🧬 HCV is often silent but serious. YHLO's Anti-HCV test detects hepatitis C antibodies using just one tube of blood with IVDR-certified accuracy.

With 100% diagnostic sensitivity and over 99% specificity, our solution is simple, authoritative, and reliable—ideal for broad screening and early intervention.

04/08/2025

🧪 YHLO provides a full hepatitis B diagnostic solution covering HBsAg, Anti-HBs, HBeAg, Anti-HBe, and Anti-HBc. These markers offer vital insights into infection status, immune response, and disease progression.

Our high-sensitivity iFlash CLIA platform enables early detection and effective monitoring to support better patient outcomes.

01/08/2025

🧬 From liver function testing to cancer screening, YHLO delivers a truly comprehensive solution for liver disease diagnostics.

Powered by our CLIA platform, we offer an integrated approach to the detection, classification, and monitoring of a full range of liver conditions — including viral hepatitis (A/B/C/D), autoimmune liver diseases (AIH, PBC, PSC), fatty liver, fibrosis, and liver cancer — all within one streamlined workflow.

Whether it’s assessing liver function, predicting disease risk, staging fibrosis, or screening for malignancy, YHLO provides timely, accurate, and clinically actionable results to support better patient care.

29/07/2025

📣 Join Us at CHINA HOSPEQ 2025 – Booth K11

Where automation meets innovation — YHLO is bringing iTLA Max to the spotlight at CHINA HOSPEQ 2025!

📍 China National Convention Center, Beijing
📅 August 15–17, 2025
📌 Booth No. K11

Designed for seamless integration, high throughput, and intelligent connectivity, iTLA Max empowers laboratories to achieve new levels of efficiency, flexibility, and precision.

We look forward to welcoming you in Beijing and shaping the future of intelligent diagnostics — together!

Address

YHLO Biopark, Baolong 2nd Road, Baolong Subdistrict
Shenzhen
518000

Telephone

+8675526601910

Website

https://en.szyhlo.com/

Alerts

Be the first to know and let us send you an email when YHLO posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to YHLO:

Shortcuts

Want your practice to be the top-listed Clinic in Shenzhen?